EX-21.1 24 v216923_ex21x1.htm

## EXHIBIT 21.1

Subsidiaries of NeoStem, Inc.(1) |  | Jurisdiction of Incorporation/Organization
NeoStem Therapies, Inc. |  | Delaware
Stem Cell Technologies, Inc. |  | Florida
NeoStem (China), Inc. |  | People’s Republic of China
CBH Acquisition LLC |  | Delaware
China Biopharmaceuticals Holdings, Inc.(2) |  | Delaware
Suzhou Erye Pharmaceuticals Company Ltd.(2) |  | People’s Republic of China
Progenitor Cell Therapy, LLC |  | Delaware
PCT Allendale, LLC(3) |  | New Jersey
DomaniCell, LLC(3) |  | Delaware
Athelos Corporation(4) |  | Delaware

| (1) | Unless otherwise specified, each entity listed in the chart is a wholly-owned direct subsidiary of NeoStem, Inc.

| (2) | China Biopharmaceuticals Holdings, Inc. is a wholly-owned subsidiary of CBH Acquisition LLC and holds the 51% interest in Suzhou Erye Pharmaceutical Company Ltd. (“Erye”). Suzhou Erye Economy and Trading Co. Ltd. owns the remaining 49% interest in Erye.

| (3) | This entity is a wholly-owned subsidiary of Progenitor Cell Therapy, LLC.

| (4) | Progenitor Cell Therapy, LLC holds an 80% interest in this entity.